Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Eduardo Polo Marqués
Observed names:
E Polo Marques,
E. Polo Marques,
Eduardo Marques,
Eduardo Polo Marques
Institution:
Hospital Universitario Miguel Servet
Observed institutions:
Hospital Universitario Miguel Servet,
Hospital Clínico Universitario Lozano Blesa,
Hospital Clínico Universitario Virgen de la Victoria
ORCID:
0000-0002-6561-2097
Observed ORCID:
0000-0002-6561-2097
OpenAlex ID:
A5063433606
Management of patients with metastatic breast cancer
2011
·
Josefina Cruz Jurado
, Paula Richart Aznar
, et al.
·
Advances in Therapy
·
192
Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
2022
·
Julien Taieb
, Sara Lonardi
, et al.
·
Clinical Colorectal Cancer
·
15
PDF
Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
2020
·
Ian Chau
, Marwan Fakih
, et al.
·
Cancers
·
15
PDF
Prognostic value of serum angiogenic activity in colorectal cancer patients
2007
·
Francisco‐Jesus Gonzalez
, Ana‐Rodriguez Quesada
, et al.
·
Journal of Cellular and Molecular Medicine
·
13
PDF
Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management
2025
·
Carmen Blanco Abad
, Paula Gomila Pons
, et al.
·
Journal of Clinical Medicine
·
8
PDF
VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
2021
·
T. André
, A. Falcone
, et al.
·
Annals of Oncology
·
7
PDF
Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors
2025
·
Sara Elena Campos Ramírez
, Alejandro Andrés García
, et al.
·
Journal of Clinical Medicine
·
5
Oral vinorelbine (NVBO) in combination with trastuzumab (HER) in metastatic breast cancer (MBC): Data on efficacy and safety when administered in first- or second-line treatment.
2010
·
J. J. Illarramendi
, I. Blancas
, et al.
·
Journal of Clinical Oncology
·
5
Neumatocele
2010
·
Miguel Ángel Santolaria López
, Maider Salinas Áriz
, et al.
·
Revista Clínica de Medicina de Familia
·
3
P-386 Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer
2023
·
H. Wasan
, S. Lonardi
, et al.
·
Annals of Oncology
·
2
PDF
Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs).
2019
·
Enrique Aranda
, Pilar Garcia-Alfonso
, et al.
·
Journal of Clinical Oncology
·
1
Real-World Germline Testing Patterns and Clinical Implications of HRR-Associated Germline Variants in Pancreatic Ductal Adenocarcinoma
2026
·
Carmen Blanco Abad
, Diego Casas Deza
, et al.
·
Cancers
SEOM–GEMCAD–TTD clinical guidelines for anal cancer (2025)
2026
·
Mónica Guillot Morales
, Ana Fernández Montes
, et al.
·
Clinical & Translational Oncology
PDF
Actionable subgroups (I): RAS (KRAS G12C) and BRAF V600E
2026
·
Vicente Alonso-Orduña
, María Tobeña Puyal
, et al.
·
Revisiones en cáncer
PDF
256eP Comparative outcomes of TNT and CRT in locally advanced rectal cancer: A retrospective cohort study
2025
·
S. Ruffini Egea
, S.E. Campos Ramirez
, et al.
·
Annals of Oncology
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
2022
·
A. Rodriguez-Ariza
, M.A. Gomez España
, et al.
·
Annals of Oncology
PDF
Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.
2020
·
Thomas H. Cartwright
, Marwan Fakih
, et al.
·
Journal of Clinical Oncology
POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers
2019
·
M E Elez Fernandez
, M.A. Gómez-España
, et al.
·
Annals of Oncology
Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
2019
·
I. Chau
, M.G. Fakih
, et al.
·
Annals of Oncology
Prognostic models in advanced gastric cancer in first and second line chemotherapy treatment in Spanish population.
2017
·
Jorge Hernando-Cubero
, Natalia Alvarez-Garcia
, et al.
·
Journal of Clinical Oncology
Impact of vascular endothelial growth factor (VEGF) and hypoxia-inductible factor-1 alpha (HIF-1) expression on the prognosis of locally advanced cervical carcinoma (LACC) treated with radiochemotherapy.
2017
·
Julia Madani
, Beatriz Eizaguirre
, et al.
·
Journal of Clinical Oncology
Aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Safety and quality of life (QoL) data from the Spanish subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP).
2017
·
Fernando Rivera
, Eduardo Polo Marques
, et al.
·
Journal of Clinical Oncology
Mutaciones de brca1 y brca2 en familias aragonesas de alto riesgo de cancer de mama/ovario
2011
·
Eduardo Polo Marqués
, Alejandro Sánchez
, et al.
·
Dialnet (Universidad de la Rioja)
Osteonecrosis de mandíbula por bisfosfonatos en paciente con cancer de próstata
2008
·
Eduardo Polo Marqués
, M.A. Allende Bandrés
, et al.
·
Atención farmacéutica
Oxicodona en dolor oncológico: Experiencia clínica
2008
·
Eduardo Polo Marqués
, Laura Murillo Jaso
, et al.
·
Atención farmacéutica
Show more works
View as search
Works count:
26
Citation count:
266
H-index:
6
I10-index:
4
Year
Topic
Type